Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients.
Joe S Al-RamahiMoazzam ShahzadKevin LiShaun DeJarnetteSibgha Gull ChaudharyForat LutfiNausheen AhmedRamesh BalusuRajat BansalHaitham AbdelhakimLeyla ShuneAnurag K SinghSunil H AbhyankarJoseph P McGuirkMuhammad Umair MushtaqPublished in: Leukemia & lymphoma (2023)
We investigated the outcomes after Coronavirus disease 2019 (COVID) in hematopoietic cell transplant (HCT) or chimeric antigen receptor-T cell (CART) therapy recipients in a single-centre study including all ( n = 261)HCT/CART recipients (allogeneic-HCT 49%, autologous-HCT 40%, CART 11%). The median age was 60 (22-80) years. COVID severity was mild (74%), moderate (11%), and severe/critical (16%) with a mortality rate of 7% and a median duration of infection of 5.7 weeks. Significant predictors of COVID severe disease or mortality included concurrent infection (HR 14.9, 95% CI 2.2-5.6) and immunosuppressive therapy (OR 4.8, 95% CI 1.2-3.4).HCT/CART recipients have a higher risk of mortality with COVID and warrant vigilant interventions.
Keyphrases
- coronavirus disease
- cell therapy
- sars cov
- respiratory syndrome coronavirus
- bone marrow
- cell cycle arrest
- mesenchymal stem cells
- stem cells
- cardiovascular events
- kidney transplantation
- risk factors
- single cell
- stem cell transplantation
- physical activity
- cardiovascular disease
- cell death
- locally advanced
- pi k akt
- drug induced
- high dose
- atomic force microscopy
- low dose
- high speed
- single molecule
- mass spectrometry
- smoking cessation